These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26641242)

  • 1. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
    Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
    Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
    Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
    Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
    Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
    Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary sclerosing cholangitis: updates in diagnosis and therapy.
    Portincasa P; Vacca M; Moschetta A; Petruzzelli M; Palasciano G; van Erpecum KJ; van Berge-Henegouwen GP
    World J Gastroenterol; 2005 Jan; 11(1):7-16. PubMed ID: 15609388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Therapeutic Strategies for Primary Sclerosing Cholangitis.
    Williamson KD; Chapman RW
    Semin Liver Dis; 2016 Feb; 36(1):5-14. PubMed ID: 26870928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary sclerosing cholangitis.
    Floreani A; De Martin S
    Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary sclerosing cholangitis and bile acids.
    Chazouillères O
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel developments in IBD-related sclerosing cholangitis.
    Ponsioen CY
    Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S15-8. PubMed ID: 21640925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies target the toxic consequences of cholestatic liver disease.
    Jansen PLM
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatments of primary sclerosing cholangitis.
    Vacca M; Krawczyk M; Petruzzelli M; Sasso RC; van Erpecum KJ; Palasciano G; van Berge-Henegouwen GP; Moschetta A; Portincasa P
    Curr Med Chem; 2007; 14(19):2081-94. PubMed ID: 17691949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
    Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
    Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.